R&D costs for pharmaceutical companies do not explain elevated US drug prices

Evidence Driven Drug Pricing Project
March 7, 2017

Dr. Peter B. Bach and his team at Memorial Sloan Kettering Cancer Center compare U.S. prices of the 20 top-selling drugs globally to their counterparts in Canada, Denmark, Ireland, and the United Kingdom. The results show, on average, list prices in the other developed countries are only 43% of U.S. net drug prices. To put that in perspective, in 2015, the U.S. net prices were $112B higher than the other countries’ list prices, while the companies spent only $77B of that amount on global R&D.

Read the full article on the Health Affairs Blog.